Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

CVS Health's pharmacy benefit manager, CVS Caremark, will not immediately add Gilead Sciences' new, high-efficacy HIV prevention drug, Yeztugo (priced over $28,000 annually), to its commercial or Affordable Care Act formularies, citing clinical, financial, and regulatory factors, including alignment with current HHS recommendations. This decision presents a significant market access hurdle for Gilead, despite the drug's proven effectiveness and the company's stated aim for 75% U.S. insurer coverage by year-end, underscoring ongoing pricing pressures and the critical influence of PBMs in the U.S. pharmaceutical landscape, alongside potential future regulatory shifts impacting coverage.

Analysis

Gilead Sciences (GILD) faces a significant commercial headwind for its new, highly effective HIV prevention drug, Yeztugo, following the decision by CVS Health's pharmacy benefit manager (PBM) not to add it to commercial formularies at this time. The rationale from CVS, citing clinical, financial, and regulatory factors, underscores the challenge posed by Yeztugo's high list price of over $28,000 annually, despite its near-100% efficacy. This development highlights the immense negotiating power of the top three PBMs, which control approximately 70% of U.S. specialty drug prescriptions. While Gilead expresses confidence in achieving 75% U.S. insurer coverage by year-end, driven by positive uptake from government payers like Medicare, the VA, and several state Medicaid plans, the exclusion by a major commercial PBM like CVS puts this target at risk. The situation is further complicated by the regulatory landscape, as Yeztugo is not yet included in the U.S. Preventive Services Task Force (USPSTF) recommendations, which are crucial for mandated coverage without patient cost-sharing under the Affordable Care Act. The moderately negative sentiment for GILD (-0.4) accurately reflects this market access uncertainty, which now overshadows the drug's clinical promise.

Key Decisions for Investors

• Investors in Gilead should treat upcoming formulary decisions from other major PBMs, particularly UnitedHealth's OptumRX and Cigna's Express Scripts, as critical near-term catalysts that will validate or challenge the company's 75% coverage target for Yeztugo.
• The primary investment risk for Gilead's Yeztugo has pivoted from clinical efficacy to commercial execution and pricing, meaning forward-looking guidance on payer negotiations and net price realization should be scrutinized more heavily than historical trial data.
• A key long-term catalyst to monitor is the potential inclusion of Yeztugo in the U.S. Preventive Services Task Force (USPSTF) guidelines, as a favorable recommendation would mandate broad, no-cost-sharing coverage and significantly de-risk the drug's long-term revenue trajectory.